Abstract
An investigator blind trial was performed comparing bismuth salicylate, erythromycin ethylsuccinate, and placebo in the treatment of Campylobacter pyloridis associated gastritis in patients without peptic ulceration. Fifty patients fulfilled the study criteria. There was a strong correlation between the presence of C pyloridis and histologically confirmed gastritis. Clearance of organisms led to improvement of the gastritis. C pyloridis was cleared from 15 patients; of these, 13 had gastritis initially, which resolved in 12. Conversely, gastritis resolved in only four of 32 patients not cleared of organisms (p less than 0.0001). There was significantly greater improvement in endoscopic appearances in the patients cleared of C pyloridis compared with those whose infection persisted (p less than 0.001). In the three treatment groups organisms were cleared from 14 of 18 patients receiving the locally active bismuth salicylate, only one of 15 patients receiving erythromycin ethylsuccinate, and none of 17 patients taking placebo. These findings suggest that the ideal antimicrobial for the successful eradication of C pyloridis associated gastritis should be locally active, stable at low pH, and should penetrate gastric mucus. The resolution of gastritis and improvement in endoscopic appearances associated with clearance of C pyloridis support the view that these organisms may play a part in this condition.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Earlam R. J., Amerigo J., Kakavoulis T., Pollock D. J. Histological appearances of oesophagus, antrum and duodenum and their correlation with symptoms in patients with a duodenal ulcer. Gut. 1985 Jan;26(1):95–100. doi: 10.1136/gut.26.1.95. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goodwin C. S., Blake P., Blincow E. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrob Chemother. 1986 Mar;17(3):309–314. doi: 10.1093/jac/17.3.309. [DOI] [PubMed] [Google Scholar]
- Hamilton I., O'Connor H. J., Wood N. C., Bradbury I., Axon A. T. Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine. Gut. 1986 Jan;27(1):106–110. doi: 10.1136/gut.27.1.106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hillemand P., Pallière M., Laquais B., Bouvet P. Traitement bismuthique et bismuthémie. Sem Hop. 1977 Sep;53(31-32):1663–1669. [PubMed] [Google Scholar]
- Marshall B. J., Armstrong J. A., McGechie D. B., Glancy R. J. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust. 1985 Apr 15;142(8):436–439. doi: 10.5694/j.1326-5377.1985.tb113443.x. [DOI] [PubMed] [Google Scholar]
- McNulty C. A., Wise R. Rapid diagnosis of Campylobacter-associated gastritis. Lancet. 1985 Jun 22;1(8443):1443–1444. doi: 10.1016/s0140-6736(85)91865-3. [DOI] [PubMed] [Google Scholar]
- Nyrén O., Adami H. O., Bates S., Bergström R., Gustavsson S., Löf L., Nyberg A. Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med. 1986 Feb 6;314(6):339–343. doi: 10.1056/NEJM198602063140603. [DOI] [PubMed] [Google Scholar]
- Price A. B., Levi J., Dolby J. M., Dunscombe P. L., Smith A., Clark J., Stephenson M. L. Campylobacter pyloridis in peptic ulcer disease: microbiology, pathology, and scanning electron microscopy. Gut. 1985 Nov;26(11):1183–1188. doi: 10.1136/gut.26.11.1183. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Skirrow M. B. Campylobacter enteritis: a "new" disease. Br Med J. 1977 Jul 2;2(6078):9–11. doi: 10.1136/bmj.2.6078.9. [DOI] [PMC free article] [PubMed] [Google Scholar]